Guardant Health, Inc. $GH Shares Newly Purchased by Englebert Financial Advisers LLC

Englebert Financial Advisers LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the third quarter, HoldingsChannel reports. The firm bought 5,473 shares of the company’s stock, valued at approximately $976,000. Guardant Health makes up about 1.0% of Englebert Financial Advisers LLC’s holdings, making the stock its 24th biggest holding.

Several other hedge funds and other institutional investors have also modified their holdings of the business. ABS Investment Management LLC bought a new position in shares of Guardant Health during the second quarter valued at approximately $345,069,000. MCF Advisors LLC lifted its holdings in Guardant Health by 755.0% in the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock worth $26,000 after purchasing an additional 151 shares during the period. NFSG Corp bought a new position in shares of Guardant Health in the third quarter valued at approximately $33,000. TrinityBridge Ltd acquired a new position in shares of Guardant Health during the 2nd quarter valued at $45,000. Finally, Global Retirement Partners LLC acquired a new position in Guardant Health during the second quarter worth about $59,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Amirali Talasaz sold 37,500 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the sale, the chief executive officer owned 37,500 shares in the company, valued at approximately $6,343,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Steve Krognes sold 6,674 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the transaction, the director owned 7,906 shares of the company’s stock, valued at approximately $1,389,400.44. This represents a 45.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 178,940 shares of company stock valued at $30,070,911 in the last quarter. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Stock Up 3.0%

NASDAQ:GH opened at $162.59 on Wednesday. The company’s 50-day moving average price is $167.70 and its two-hundred day moving average price is $140.50. Guardant Health, Inc. has a 12 month low of $66.59 and a 12 month high of $191.05. The firm has a market cap of $21.82 billion, a PE ratio of -46.59 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.44) EPS. On average, research analysts expect that Guardant Health, Inc. will post -3.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. UBS Group upped their price target on Guardant Health from $175.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Tuesday, August 25th. Canaccord Genuity Group boosted their price target on Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Guggenheim raised their price objective on Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Barclays upped their price target on Guardant Health from $200.00 to $220.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $190.00.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.